Zura Bio Limited - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ZURA Nasdaq 2834 zurabio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Zura Bio Limited

Here's Why We're Not Too Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Situation - Jun 3rd, 2026 4:09 am
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - May 14th, 2026 5:30 am
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer - May 13th, 2026 5:30 am
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates - May 7th, 2026 5:30 am
One Zura Bio Insider Raised Their Stake In The Previous Year - Apr 23rd, 2026 4:06 am
Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates - Mar 19th, 2026 2:05 pm
Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress - Mar 5th, 2026 4:30 am
Zura Bio to Participate in Upcoming Investor Conferences - Mar 2nd, 2026 4:30 am
Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares - Feb 27th, 2026 4:30 am
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million - Feb 25th, 2026 1:26 pm
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges - Feb 25th, 2026 1:19 pm
Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst - Feb 25th, 2026 1:11 pm
Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants - Feb 25th, 2026 4:30 am
Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants - Feb 24th, 2026 2:01 pm
Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors - Feb 23rd, 2026 4:30 am
Zura Bio Highlights Key Phase 2 Tibulizumab Readouts at Guggenheim Biotech Summit 2026 - Feb 16th, 2026 4:03 am
Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit - Feb 4th, 2026 4:30 am
Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer - Jan 21st, 2026 6:50 am
Zura Bio Reports Business Updates and Outlook for 2026 - Jan 12th, 2026 4:30 am
December 2025's Top Penny Stocks With Promising Potential - Dec 15th, 2025 11:05 am